Mesoblast Reports $30.3 Mln Ryoncil Net Sales In Q3; Nearing $100 Mln Revenue Since Launch

Mesoblast reported nearly $100 million in revenue in the first year after launching its lead product, Ryoncil, a material commercial milestone. The result indicates meaningful initial market uptake and a positive revenue run-rate that could support modest near-term upside for the stock.

Analysis

Mesoblast reported nearly $100 million in revenue in the first year after launching its lead product, Ryoncil, a material commercial milestone. The result indicates meaningful initial market uptake and a positive revenue run-rate that could support modest near-term upside for the stock.